Health Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 James Pereira Sep 19, 2022 - CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all… Read More...
Health FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar… James Pereira Aug 3, 2022 - CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023… Read More...
